In TP53MUT AML‐MRC patients, concurrent DNMT3A mutation was associated with inferior OS (HR 2.12, 95% CI 1.20–3.76, p = 0.0083) and EFS (HR 1.96, 95% CI 1.11–3.45, p = 0.018), while in TP53WT patients, DNMT3A mutation did not significantly impact OS (HR 0.81, 95% CI 0.51–1.30, p = 0.39) or EFS (HR 0.84, 95% CI 0.55–1.28, p = 0.41) (Figure S9A,B). This evidence concerns the gene DNMT3A and acute myeloid leukemia.